Research record
BRAF V600-mutant melanoma
A BRAF V600 result can open a targeted-therapy conversation with BRAF plus MEK inhibitor combinations, alongside immunotherapy and trial questions.
What this is
A BRAF V600 result can open a targeted-therapy conversation with BRAF plus MEK inhibitor combinations, alongside immunotherapy and trial questions.
Why it may come up
- BRAF/MEK combinations are FDA-approved in several melanoma contexts.
- The stage, prior treatment, and country determine whether the conversation is adjuvant, has spread, or trial-based.
What not to assume
- Confirm the exact BRAF variant, usually V600E or V600K for common melanoma approvals.
- Do not treat BRAF-targeted therapy as interchangeable with NRAS-directed strategies.
- Gene
- BRAF
- Cancer type
- melanoma
- Last checked
- 2026-05-20
What we know
- BRAF/MEK combinations are FDA-approved in several melanoma contexts.
- The stage, prior treatment, and country determine whether the conversation is adjuvant, has spread, or trial-based.
- BRAF-positive status can affect whether later therapies such as lifileucel fit the situation.
What is unclear
- Confirm the exact BRAF variant, usually V600E or V600K for common melanoma approvals.
- Do not treat BRAF-targeted therapy as interchangeable with NRAS-directed strategies.
Questions to ask
- Which parts of this result are actionable?
- Which parts are mainly useful for trial search?
- Would a melanoma specialty center review change the conversation?